KeynoteMolecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary
Introduction
Based on estimations, 23 000 men and women (55% of this number being men) will be diagnosed with a primary brain or other nervous system malignancy this year in the USA, with 13 700 men and women succumbing to these diseases [1]. Glioma is the most common primary central nervous system (CNS) tumour. Widespread infiltration of surrounding tissue, the presence of necrotic tissue and/or angiogenic activity characterise the most malignant form termed glioblastoma (GBM) grade IV [2]. The standard of care for treatment of GBM consists of neurosurgical tumour resection and concomitant chemotherapy and radiotherapy (RT) followed by adjuvant chemotherapy. The most widely implemented treatment regimen has been developed by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group, and is often referred to as the ‘Stupp protocol’. In a randomised trial including almost 600 patients improved overall survival was clearly demonstrated in patients who received a combined modality treatment of temozolomide (TMZ) chemotherapy in conjunction with concomitant RT followed by adjuvant or maintenance TMZ for six cycles (TMZ/RT → TMZ), compared with patients who received only RT as the initial treatment but might have received TMZ chemotherapy at recurrence [3]. Nevertheless, despite the emergence of novel treatment strategies in recent years (discussed in detail below), survival rates for GBM patients continue to be low. According to the National Cancer Institute median survival for patients with GBM is 15 months from time of diagnosis [1].
Development of novel therapeutics with anti-GBM activity remains a crucial and challenging objective. Targeting a single ‘cancer hallmark’ [4] is unlikely to elicit significant benefit in patients presenting with advanced malignancies. Thus, developing molecular targeted drugs that concomitantly impact several GBM survival pathways/cancer hallmarks is likely to represent a new horizon within the field. However, notwithstanding the validity of this objective, the average cost of developing a drug within the healthcare space has increased to an average of US$ 1.3 billion over several years with sustained investment required over a period of no less than ten years. This is none more evident than in the oncology space, where molecular targeted therapies (in the context of the evolution of a personalised treatment paradigm) comprise a significant sector of the market.
Reducing the drug development time-line through implementation of molecular imaging (MI) strategies during preclinical and clinical development phases would significantly reduce the burden of cost. MI can improve the efficiency of drug screening and can be used to interrogate drug pharmacokinetics and biodistribution, thus markedly reducing time and costs required for the development of a new drug. Moreover, identification of MI biomarkers yielding spatial and temporal information could also provide surrogate clinical endpoints. Crucially, imaging of key biological processes that underpin the classical cancer hallmarks [4] (e.g. angiogenesis, invasion, proliferation) might provide a more robust mechanistic assessment of newly emergent molecular targeted therapeutics that represent a cornerstone of personalised medicine. This is of note when one considers that chronic treatment with targeted therapies results in disease stabilisation rather than the tumour shrinkage more evident in response to cytotoxic therapies. As such, classical gross anatomical imaging of tumour lesions can no longer provide optimal therapeutic follow up; what is currently required are imaging modalities that enable sensitive assessment of drug effects at the level of specific targeted molecular features and/or biological pathways.
MI optimises, streamlines and refines the drug development process. The advantages of implementing a MI strategy during the preclinical and clinical development stages are clearly illustrated in terms of translational research in primary brain tumours. The disease represents particular challenges towards development of novel therapeutics, because drugs must be amenable to crossing the blood–brain barrier (BBB), notwithstanding BBB breakdown during the disease process, and should efficiently compromise the key processes of tumour angiogenesis, invasion and cell proliferation. The ability to monitor drug effects on these key biological processes in real time will play a key part in elucidating the next generation of molecular targeted anti-GBM therapeutics. Within the context of the current review, we have, for the first time, gathered a multidisciplinary team harnessing expertise in cell biology, preclinical modelling, neurosurgery, MI and neuro-oncology to assess the role played by MI critically in the development of a state-of-the-art next-generation anti-GBM therapeutic paradigm that will seek to target multiple cancer hallmarks.
Section snippets
Preclinical and clinical molecular imaging strategies applied in GBM
Longitudinal monitoring of tumour progression and drug efficacy are possible thanks to real-time noninvasive imaging technologies. These technologies facilitate quantitative and qualitative imaging of the primary tumour and record the extent of infiltration into the brain parenchyma. State-of-the-art MI modalities used to assess GBM in preclinical and/or clinical settings include tomographic imaging, nuclear-radioisotope-based imaging, optical imaging and intra-operative photodynamic navigation
Application of MI strategies in the preclinical development and clinical evaluation of a novel GBM therapeutic paradigm
The increasing use of MI in translational GBM research as well as evolution of the GBM imaging field has facilitated preclinical and clinical interrogation of gold-standard and next-generation therapeutics. The expanding complexity of the MI space, including novel MR techniques and PET-based approaches, supports the emergence of a novel GBM treatment paradigm based on the targeting of multiple cancer hallmarks and is likely to result in the identification of new imaging as well as therapeutic
Concluding remarks and future directions
MI is increasingly emerging as a crucial tool existing at the interface between preclinical and clinical translational research towards identification of a next-generation GBM therapeutic paradigm. Availability of reliable preclinical animal models that recapitulate the human pathology, when combined with suitable, state-of-the-art, translational imaging modalities, has to date facilitated significant advances in the field. Implementation of imaging protocols during preclinical development of
Acknowledgements
Funding is acknowledged within the context of the Irish National Biophotonics and Imaging Platform and the European Commission Framework Programme 7 AngioTox and AngioPredict initiatives.
Annette T. Byrne is Senior Lecturer in Human Physiology, Principal Investigator Tumour Biology/Molecular Imaging at the Royal College of Surgeons in Ireland and Visiting Lecturer/Conway Fellow at University College Dublin, Ireland. She obtained a PhD in Cell Biology from the University of York, UK, in 1999, following which she was awarded the prestigious University of California San Francisco John Kerner Fellowship in gynaecologic oncology. She transitioned to Industry in 2001 (Pharmacyclics;
References (104)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Lancet Oncol.
(2009)- et al.
Hallmarks of cancer: the next generation
Cell
(2011) - et al.
MR contrast enhancement of intracranial lesions with Gd-DTPA
Radiol. Clin. North Am.
(1988) Advanced MRI of adult brain tumors
Neurol. Clin.
(2007)Evoked-cerebral blood oxygenation changes in false-negative activations in BOLD contrast functional MRI of patients with brain tumors
Neuroimage
(2004)Direct comparison of thallium-201 and technetium-99 m MIBI SPECT of a glioma by receiver operating characteristic analysis
J. Clin. Neurosci.
(2009)Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging
Neoplasia
(2000)Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
Lancet Oncol.
(2006)VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
Cancer Cell
(2012)Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
Int. J. Radiat. Oncol. Biol. Phys.
(2011)
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Drug Discov. Today
Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma
Neuroimage
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis
Neoplasia
Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain
Mol. Ther.
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2
Cell
In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model
Biomaterials
Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model
Neoplasia
MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation
Int. J. Radiat. Oncol. Biol. Phys.
The 2007 WHO classification of tumours of the central nervous system
Acta Neuropathol.
Advanced MRI in the management of adult gliomas
Br. J. Neurosurg.
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma
Clin. Cancer Res.
Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors
Acta Radiol.
Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging
AJNR Am. J. Neuroradiol.
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab
Magn. Reson. Med.
Arterial spin-labeled perfusion MRI in basic and clinical neuroscience
Curr. Opin. Neurol.
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
Neuro Oncol.
Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema
J. Neurooncol.
Molecular imaging of gliomas with PET: opportunities and limitations
Neuro Oncol.
Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography
AJNR Am. J. Neuroradiol.
Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates
J. Neurooncol.
Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme
Eur. J. Nucl. Med. Mol. Imaging
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis
J. Nucl. Med.
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Nat. Med.
(18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas
Eur. J. Nucl. Med. Mol. Imaging
Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent
J. Nucl. Med.
Small-animal SPECT and SPECT/CT: important tools for preclinical investigation
J. Nucl. Med.
Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy
Ann. Nucl. Med.
123I-IMT SPECT for evaluation of the response to radiation therapy in high grade gliomas: a feasibility study
Br. J. Radiol.
Noninvasive real-time in vivo bioluminescent imaging of gene expression and of tumor progression and metastasis
Ernst Schering Res. Found. Workshop
Imaging in the era of molecular oncology
Nature
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model
Mol. Imaging Biol.
Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors
Clin. Nucl. Med.
Multimodality imaging: an update on PET/CT technology
Eur. J. Nucl. Med. Mol. Imaging
Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect
Neurosurgery
Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy
Mol. Imaging
Optical imaging of Cerenkov light generation from positron-emitting radiotracers
Phys. Med. Biol.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
J. Clin. Oncol.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
J. Clin. Oncol.
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
Cancer Res.
Cited by (15)
<sup>99m</sup>Tc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications
2015, Thrombosis ResearchCitation Excerpt :The antitumor activity of ixolaris is believed to derive from its ability to interact with tumor-expressed TF and the subsequent inhibition of PAR2 signaling [28]. Molecular imaging plays a critical role in diagnosis and therapeutics [29]. In this context, TF was recently reported as a potential target for imaging TF-expressing tumors [30–33].
PARPi-FL - A Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
2014, Neoplasia (United States)Citation Excerpt :Still, progression-free survival is only modestly improved with the use of these techniques [25,26]. There is thus a need for better tools for intraoperative imaging [27,28]. In order to expand the portfolio of potential clinically relevant intraoperative probes, we investigated the potential of PARPi-FL to act as an agent to macroscopically delineate between high PARP1 and low PARP1 expressing tissues.
Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
2022, Cancer Chemotherapy and PharmacologyDNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance
2020, Genetics and Molecular Biology
Annette T. Byrne is Senior Lecturer in Human Physiology, Principal Investigator Tumour Biology/Molecular Imaging at the Royal College of Surgeons in Ireland and Visiting Lecturer/Conway Fellow at University College Dublin, Ireland. She obtained a PhD in Cell Biology from the University of York, UK, in 1999, following which she was awarded the prestigious University of California San Francisco John Kerner Fellowship in gynaecologic oncology. She transitioned to Industry in 2001 (Pharmacyclics; Angion Biomedia; Oncomark) where she held a number of senior preclinical drug development roles implementing clinically relevant tumour models and state of the art molecular imaging strategies. On her return to Ireland and academia in 2005 she played a key role in establishing Ireland's first preclinical multimodality molecular imaging core facility at University College Dublin and is currently a National Biophotonics and Imaging Platform Ireland Investigator (http://www.nbipi.ie). Furthermore, she is Principal Investigator and Coordinator of two multimillion European Commission funded research platforms in the translational oncology/molecular imaging space (http://www.angiotox.com/; https://www.angiopredict.com/). Her research focus implements multimodality imaging approaches towards evolution of improved anticancer therapeutics.